In this report, they show how rosiglitazone, a PPARγ agonist used to treat diabetes as an insulin sensitizer, activates the expression and secretion of this miRNA by adipose tissue, causing cardiomyocyte hypertrophy through the diminution of Hamartin or Tuberous sclerosis 1 protein (TSC1) and subsequent induction of mTOR signaling [56]. The gene discussed is TSC1; the disease is diabetes mellitus.